A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
Public ClinicalTrials.gov record NCT03910660. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases, Administered in Combination With the Anti-Programmed Cell Death 1 Monoclonal Antibody Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype
Study identification
- NCT ID
- NCT03910660
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- BioXcel Therapeutics Inc
- Industry
- Enrollment
- 98 participants
Conditions and interventions
Interventions
- BXCL701 monotherapy Drug
- BXCL701 plus Pembrolizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 11, 2019
- Primary completion
- Oct 30, 2023
- Completion
- Aug 30, 2025
- Last update posted
- May 14, 2026
2019 – 2025
United States locations
- U.S. sites
- 9
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Francisco (UCSF) | San Francisco | California | 94158 | — |
| BioXcel Clinical Research Site | Denver | Colorado | 80211 | — |
| Yale University | New Haven | Connecticut | 06510 | — |
| Moffitt Cancer Center and Research Institute | Tampa | Florida | 33612 | — |
| BioXcel Clinical Research Site | Detroit | Michigan | 48201 | — |
| Center for Advanced Medicine / R.J. Zuckerberg Cancer Center (Northwell Health Cancer Institute) | Lake Success | New York | 11042 | — |
| Weill Cornell Medicine New York | New York | New York | 10021 | — |
| White Plains Hospital Center for Cancer Care | White Plains | New York | 10601 | — |
| The Ohio State University | Columbus | Ohio | 43210 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03910660, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 14, 2026 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03910660 live on ClinicalTrials.gov.